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Abstract
The vaccine Canileish R© is distributed in Europe to reduce the risk of developing an active infection and
clinical leishmaniosis. An English Setter dog vaccinated with Canileish R© and treated with anti-feeding
and repellent medications showed typical clinical signs of leishmaniosis. The dog was presented with
dysorexia, weight loss, fever and forelimb lameness. The physical exam revealed moderate generalized
external lymph node enlargement, sero-purulent ocular discharge, photophobia, and swollen and painful
right carpal joint. Clinico-pathological findings revealed moderate microcytic-hypochromic non-regenerative
anemia, mild neutropenia and thrombocytopenia, hyperglobulinemia, hematuria and mild elevation of urine
protein-to-creatinine ratio, polyclonal peak in the gamma globulins, Leishmania spp. amastigotes in lymph
nodes and bone marrow, and immunofluorescence antibody titer (IFAT) of 1:5120. The successful treatment
included meglumine antimonate and allopurinol for 40 days, and metronidazole-spyramicin for 24 days.
The dog was monitored up to 9 months and normalization of most hemato-biochemical abnormalities was
achieved. The bone marrow qPCR for Leishmania infantum was negative, while IFAT was 1:160. Despite the
systematic leishmaniosis prevention, the typical clinical disease can occur.
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Introduction
A vaccine for canine leishmaniosis (Canileish R©) has been
introduced in several European countries including Italy1,
starting from 2011. Its formulation origins from LiESAp
(culture supernatant of L. infantum promastigotes) and the
54-kDa excreted protein of Leishmania infantum in addition
to muramyl dipeptide (MDP) as adjuvant. The vaccine is
designed to stimulate an active immunity (cell-mediated) in
Leishmania sero-negative dogs in order to reduce the risk of
developing an active infection (12% in vaccinated vs. 33%
in control dogs) and related clinical disease (7% vs. 23%)
after the exposure to L. infantum. The overall coverage
is expected to reach 68% (2, 3, 7, 8, 9). Recently, a case
series of sixteen dogs affected by clinical leishmaniosis pre-
viously vaccinated with Canileish R© have been reported as
an Abstract (10). Here, a case of a dog regularly immunized
with Canileish R© and treated with anti-feeding and repellent
medications presenting with a severe form of leishmaniosis,
is described.
Material and Methods
“Alba”, an English setter dog, intact female of about 4 years
old was referred to the authors’ facility for dysorexia, weight
loss, fever and forelimb lameness (beginning of March
2015). “Alba” was living with 2 other dogs (both nega-
tive on Leishmania IFAT, Indirect Fluorescence Antibody
test and conjunctival PCR, Polymerase Chain Reaction) in
1Canileish; VirbacS.r.l., Milan, Italy (A.I.C., Italian marketing autho-
rization, #104281062)
Northern Tuscany (Italy), and was used for hunting. “Alba”
was regularly vaccinated since the age of 3 months with vac-
cines against distemper, viral hepatitis, adenovirus, and lep-
tospirosis2. Furthermore, from the age of 9 months she was
regularly vaccinated against Leishmania using Canileish R©
according to the manufacturer’s instruction. Before the vac-
cination with Canileish R©, “Alba” underwent a complete
physical examination and partial hemato-biochemical anal-
ysis including a Speed-Leish K R© test. Following the man-
ufacturer’s instruction on Canileish R©, prophylaxis against
ectoparasites was concurrently applied (repellent and anti-
feeding, imidacloprid and permethrin3, heartworm preven-
tion with moxidectin4). After the admission (T0) a follow-
up period of 9 months at different days (T6, T10, T24, T42,
T85, T148, T265) for “Alba” was performed.
At physical examination the body condition score was
2/9 (Figure 1 and 2) and the temperature was 39.6◦C. In
addition, moderate generalized peripheral lymph node en-
largement (Figure 3 and 4), sero-purulent ocular discharge
with photophobia (Figure 5) and swollen and painful right
carpal joint (Figure 6), were recorded. Complete blood
count (CBC) including the stained blood smear evalua-
tion, serum biochemical profile (including total calcium,
phosphates, iron, total proteins, albumin, fructosamine, C-
reactive protein, urea, creatinine, total bilirubin, choles-
terol, triglycerides, glucose, alkaline phosphatase, gam-
2Nobivac CEPPi+L; Intervet Italia S.r.l., Peschiera Borromeo, MI, Italy
3Advantix; Bayer Animal Health, Milan, Italy
4Guardian Sr injectable; Eli Lilly Italia S.p.a., Sesto Fiorentino, FI,
Italy
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Figure 1. Body condition score 2/9 from the rear
view at T0
Figure 2. Body condition score 2/9 from the
front view at T0
maglutamyl transferase, aspartate amino transferase, alanine
amino transferase, creatin phosphokinase, lactate dehydro-
genase, amylase, sodium, potassium, chloride and bicar-
bonate), coagulation profile (including prothrombin time,
partial thromboplastin time, and fibrinogen), serum protein
electrophoresis (separation on albumin, alpha 1 and 2 globu-
lins, beta 1 and 2 globulins, and gamma globulins), serology
for L.infantum (cut-off value: negative for exposure, 1:160
for possible disease), complete urinalysis including UP/C
ratio, fine needle aspirations for cytology of prescapular
and popliteal lymph nodes and aspiration of bone marrow,
were performed. A sample of bone marrow aspirate was
also submitted for Leishmania quantitative PCR (qPCR).
Results
The presenting physical complaints resolved at different
times: body weight progressively gained and normalized
at T42, fever lasted for 10 days, photophobia disappeared
by day 10 but blepharitis occurred at T3 (Figure 7 and 8),
persisted at T10 (Figure 9), and disappeared at T24 (Figure
11), sero-purulent ocular discharge decreased over 15 days,
lymph nodes were almost normal by T24, and forelimb
lameness disappeared by T3. It should be noticed that at
T10 a large ulcer at the tail was evidenced (Figure 10), but
almost completely recovered at T24 (Figure 12).
The CBC initially showed a moderate microcytic-hy-
pochromic non-regenerative anemia (Hematocrit, Hct 23.9%,
reference ranges, RR, 37.3-61.7%; Mean Corpuscular Vol-
ume, MCV 54.7 fl, RR 61.6-73.5; Mean Corpuscular He-
moglobin Content, MCHC 35.6 g/dL, RR 32.0-37.9; Mean
Corpuscular Volume, MCH 19.5 pg, RR 21.2-26.9; reticulo-
cytes 17.0 K/µL, RR 10-110), mild neutropenia (3.0 K/µL,
RR 3.7-11.9), normal lymphocyte count with reactive lym-
phocyte and mild thrombocytopenia (132 K/µL, RR 148-
484). Starting from T3, the microcytic hypochro-mic RBCs
slowly returned to normal by T85, the neutrophil count nor-
malized by T10, the reactive lymphocytes disappeared from
blood smears by T85 and the platelet count normalized by
T10. The CBC was normal at T148 although few nucleated
RBCs and Howell-Jolly bodies were observed. At T265 the
CBC was within the reference ranges for all parameters.
The biochemical profile showed, initially, severe hy-
perproteinemia (11.5 g/dL, RR 5.8-7.8) (normal at T85)
with low albumin (1.9 g/dL, RR 2.6-4.1) (normal at T42),
hyperglobulinemia (9.7 g/dL, RR 2.5-4.5) and low albu-
Figure 3. Popliteal lymph node enlargement at
T0
Figure 4. Prescapular lymph node enlargement
at T0
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Figure 5. Photophobia at T0 Figure 6. Carpal joint swollen at T0
min/globulins ratio (0.2, RR 0.5-1.5) (both normal at T85),
elevated C-reactive protein (2.3 mg/dL, RR 0.0-0.3) (nor-
mal at T24), slight increase of AST (75 U/L, RR 15-40)
and LDH (338 U/L, RR 20-160) (normal at T24). Then,
from T42 the biochemical profile was unrewarding and all
parameters were within the reference ranges.
The coagulation profile was investigated at T0, T27,
T148 and T265, and was always normal during the disease
course.
The serum protein electrophoresis at T0 (Figure 13A)
showed hypoalbuminemia (22.2%) and a polyclonal peak in
the gamma globulins (55.2%) that returned slowly to normal
at T148 (Figure 13B). At T265 this assay was unremarkable.
The urinalysis initially showed hematuria (normal at T6)
and mild elevation of urine protein-to-creatinine ratio (0.64,
RR 0.1-0.5) (normalized at T85). In successive samplings
all the urine parameters were within the references ranges.
At admission (T0) the lymph-node aspirates showed
lympho-plasmacellular hyperplasia with Leishmania ama-
stigotes extracellularly and in the macrophages; further aspi-
rations were not performed because the lymph nodes were
almost not palpable by T42. The bone marrow aspirate at
T0 yielded mild hyperplasia of myeloid series (as compared
to erythroid series), and slight infiltration with plasmacells
and macrophages showing Leishmania amastigotes. The
bone marrow aspirate at T148 yielded mild dysplasia in the
myeloid series and slight prevalence of erythroid cells (as
compared to myeloid). At T265 the bone marrow evaluation
was normal.
Quantitative PCR (qPCR) performed on bone marrow
samples was negative for Babesia spp, Bartonella spp,
Ehrlichia canis, Hepatozoon spp, and Rickettsia spp but
extremely positive for L. infantum (1,212,000,000 copies).
The bone marrow qPCR, repeated at T148 and T265, was
negative for L. infantum. At admission (T0) IFAT titer was
extremely high (1:5120) and the Speed-Leish K R© assay for
Leishmania spp. was positive. The IFAT titer was reduced at
T148 (1:320) and T265 (1:160) whereas the Speedy-Leish
K R© test was still positive.
“Alba” was treated with a combination of meglumine
antimonate5 (subcutaneous, SC) and allopurinol6 (per os,
PO) for 40 days; the dosage of the former was progressively
increased from 85 to 94 mg/kg, q24h while the dosage of
the latter was tapered from 8.6 to 7.8 mg/kg, q12h. Later,
allopurinol was administered from day 42 to day 85 at 7.4
mg/kg, q12h, from day 85 to day 148 at 4.8 mg/kg, q12h,
and then discontinued at T265. A course of metronidazole-
5Glucantime, Merial Italia S.p.a., Milan, Italy
6Allopurinolo generic, Sandoz S.p.a., Origgio, VA, Italy
Figure 7. Blepharitis of the left eye at T3 Figure 8. Blepharitis of the right eye at T3
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Figure 9. Blepharitis of both eyes at T10 Figure 10. Alopecia and ulcer on the tail at T10
spyramicin7 (PO) was given up until T24 (starting at 42,860
IU/kg + 7.14 mg/kg and ending at 40,540 IU/kg + 6.75
mg/kg). Fluid therapy (saline and dextrose 5%) was pro-
vided for about 10 days, the topical treatment for the ocular
complication based on eye-drops with a combination of
7Stomorgyl, Merial Italia S.p.a., Milan, Italy
neomycin and chloramphenicol8 (q12h) was discontinued
at T40, and the topical treatment for the skin lesion at the
tail was started at T6 and continued up to T24 with a com-
bination of iodopovidone9 and ointment based on glycol-
8Antibioptal, Farmila-Thea Farmaceutici S.p.a., Settimo Milanese, MI,
Italy
9Iodopovidone, Farmacare S.r.l., San Pietro in Casale, BO, Italy
Figure 11. Blepharitis of the eyes in
improvement at T24
Figure 12. Alopecia and complete recovery of
the ulcer in the tail at T24
Figure 13. (A) serum protein electrophoresis showing a
polyclonal peak in the gamma globulins at T0; (B) serum
protein electrophoresis normalized at T148
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propylene + malic acid + benzoic acid + salicylic acid10
administered both at q12h.
Discussion and conclusion
This case describes a typical clinical presentation of leish-
maniosis in a dog where breakdown of Leishmania vaccine
or ineffective/insufficient immunity can be documented (4,
6). The case was promptly reported to the Italian Agency
for Drug Surveillance in Veterinary Medicine (5). The dis-
tinction between the breakdown and ineffective/insufficient
immunity could not be established as it is not common to
test for ineffective/insufficient immunity as in other infec-
tious disease. Indeed, all the serological assays available are
directed at assessing the contact or exposure to Leishmania
by a dog that could develop active infection and/or clinical
disease (1).
Recently, a poster presented in an European Conference
reported a case series of sixteen dogs affected by clini-
cal signs of leishmaniosis, and previously vaccinated with
Canileish R© in Spain (10). The classical clinical presentation
of leishmaniosis was observed in all cases and the diagnosis
was based on direct visualization of Leishmania amastig-
otes by cytology, and indirectly by immunohistochemistry
or molecular techniques. The majority of cases included
were purebred, large and male dogs. Most of the dogs were
diagnosed with clinical leishmaniosis prior to the first an-
nual re-vaccination, and the time span between vaccination
and appearance of clinical illness was 2-12 months.
The dog described in this case came from an area where
leishmaniosis is known to be endemic and, therefore, at risk
of developing the disease. However, the owner, a physician
strictly bounded with the dog, confirmed that the use of
repellent and anti-feeding agents was correctly provided to
each of the three dogs living all together. All vaccination
schemes were also accurately performed. Indeed, Alba was
receiving the first vaccination plan in 2012 at 9 months
of age, and the annual boosters in 2013 and 2014 spring-
time. The time elapsed from the last vaccination to the
appearance of clinical signs of leishmaniosis was about 10
months. Before each annual booster the dog was screened
with Speedy-Leish K R© test that resulted negative.
“Alba” showed severe and typical clinical and clinico-
pathological signs of Leishmania infection, and promptly
responded to standard therapy (1, 9). All the clinical signs
described resolved by T27, while the clinico-pathological
signs returned to normal at different times. Indeed, while
CBC results progressively returned to normal at T265, it
should be noticed that at T165 the appearance of few nucle-
ated RBCs along evidence of Howell-Jolly bodies coupled
with bone marrow aspirate results showed some signs of
hemopoetic dysplasia both in erythroid and myeloid se-
ries. Thereafter, the bone marrow sampling at T265 was
normal. The occurrence of microcytic-hypochromic non-
regenerative anemia at presentation may suggest that the
clinical disease was started being present at least 3-4 months
before the first admission, as RBCs half-life is 110 days.
Therefore, the dog might have been infected in the summer-
autumn 2014.
10Dermaflon, Zooetis Italia S.r.l, Rome, Italy
The biochemical profile was unrewarding from T42,
and on the following monitoring. Surprisingly, the coagu-
lation profile was always normal and particularly, the fib-
rinogen was never elevated despite the clinical and clinic-
pathological evidence of an inflammatory process. The
hallmark of the chronic disease often used for monitoring
the leishmaniosis course besides the serum protein elec-
trophoresis, was strongly modified at the initial stages but
returned to normal at T148. The urinalysis followed almost
the serum biochemical pattern and returned to normal by
T85. The immediate diagnosis of leishmaniosis was carried
out with the fine needle lymph node and the bone marrow
aspirations. These two cytological assays belong to the gold
standard procedures in terms of specificity and sensitivity
to diagnose leishmaniosis. With appropriate therapy the
sensitivity of both assays to recognize the disease is decreas-
ing to almost zero. Of course, parasite culture could be
considered but it is not suitable for rapid diagnosis, and is
currently used only for research purposes. On the contrary,
the qPCR can help to detect if the pathogen is still present.
Serological tests, which can be time consuming if not “in
house available”, are the evidence of antibodies - a long
lasting immunological response, and cannot be used for
detecting the presence of the parasite (1, 6).
Additional drugs used to manage concurrent clinical
signs were also successful in controlling all abnormalities
in a short period of time. The initial administration of
metronidazole-spyramicin was chosen in order to keep the
dog under antibacterial coverage along with the specific
therapy against leishmaniosis. The qPCR investigation,
which was negative after the treatment, confirmed that the
therapy instituted was beneficial.
Even if the claim of the Canileish R© vaccine is expected
to reduce the risk of developing an active infection, the pos-
sible immunity breakdown or ineffective/insufficient immu-
nity and the clinical appearance of the clinico-pathological
signs of disease should be kept in consideration, especially
in the high risk area for Leishmania infection. The clini-
cal and clinico-pathological signs of the dog reported here
are not substantially different from the dogs not using the
vaccine affected by leishmaniosis. The immunity against
Leishmania should be evaluated by serological titers along
with the qPCR performed either on lymph node or bone mar-
row aspirate samples. Furthermore, as reported by Solano-
Gallego (10), the use of an accurate screening with diag-
nostic tests for Leishmania infection prior to vaccination in
dogs living in endemic areas should be highly considered.
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Supplement
Table 1. Clinical monitoring of Alba
T0 T3 T10 T24
Weight kg 17.5 17.7 18.5 19.1
BCS 2/9 2/9 3/9 3/9
Temperature ◦C 39.6 39.2 38.9 38.3
Pulse ppm 104 120 110 80
Breath bpm 36 32 30 15







and blepharitis Mild blepharitis
Lymphatic
lymph node enlargement


















and large ulcer on the tail
Only alopecia on the tail
Notes: at T42, T85, T148 and T265 clinical signs were unremarkable and Alba gained her body weight of 21 kg with a
normal BCS (Body Condition Score) of 4/9
NtR -nothing to report
Table 2. CBC monitoring of Alba
Analyte Reference Ranges Units T0 T6 T10 T24
RBC 5.66-8.87 M/µL 4.37 4.48 4.53 4.66
HCT 37.3-61.7 % 23.9 25 26 27.8
HGB 13.1-20.5 g/dL 8.5 8.8 9 9.7
MCV 61.6-73.5 fL 54.7 55.8 57.4 59.7
MCH 21.2-26.9 pg 19.5 19.6 19.9 20.8
MCHC 32.0-37.9 g/dL 35.6 35.2 34.6 34.9
RDW 13.6-21.7 % 17.4 17.5 18.9 21.1
Retics 10.0-110.0 K/µL 17 30.9 62.5 72.2
Estimate Retics <60.0 K/µL 21.9 22.4 68 93.2
WBC 5.05-16.76 K/µL 5.23 4.68 8.04 6.96
NEU 3.7-11,9 K/µL 3.03 2.62 3.84 4.45
BAND 0.0-0.3 K/µL 0 0 0 0
LYM 0.7-5.1 K/µL 1.46 1.59 3.52 1.81
MONO 0.2-1.7 K/µL 0.63 0.37 0.64 0.28
EOS 0.1-1.35 K/µL 0.1 0.09 0 0.42
BASO 0.0-0.1 K/µL 0 0 0 0
PLT 148-484 K/µL 132 123 338 363
MPV 8.7-13.2 fL 10.8 NA 9.9 9.6




















TPP refractometer 5.8-7.8 g/dL 10 10 10.4 10.5
Notes: ND- not determined
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Table 2. CBC monitoring of Alba (Continued)
Analyte Reference Ranges Units T42 T85 T148 T265
RBC 5.66-8.87 M/µL 5.45 5.49 5.78 5.64
HCT 37.3-61.7 % 33.4 33.9 37.8 35.5
HGB 13.1-20.5 g/dL 11.5 11.8 13.2 12.6
MCV 61.6-73.5 fL 61.3 61.7 65.4 66.5
MCH 21.2-26.9 pg 21.1 21.5 22.8 23.4
MCHC 32.0-37.9 g/dL 34.4 34.8 34.9 35.2
RDW 13.6-21.7 % 20.5 19.5 15.3 15.3
Retics 10.0-110.0 K/µL 40.9 34.6 79.2 40.1
Estimate Retics <60.0 K/µL ND ND ND ND
WBC 5.05-16.76 K/µL 6.97 8.43 8.21 8.91
NEU 3.7-11,9 K/µL 3.15 3.96 4.06 5.31
BAND 0.0-0.3 K/µL 0.07 0 0 0
LYM 0.7-5.1 K/µL 3.36 2.53 3.77 2.68
MONO 0.2-1.7 K/µL 0.14 1.18 0.2 0.71
EOS 0.1-1.35 K/µL 0.28 0.67 0.16 0.2
BASO 0.0-0.1 K/µL 0 0.08 0 0
PLT 148-484 K/µL 410 306 278 315
MPV 8.7-13.2 fL 9.4 9.6 9.5 9.1
Estimate PLT Adequate Adeguate Adequate Adequate Adequate
RBC morphology Anysocytosis +
Anysocytosis +,
Keratocyte +/-




WBC morphology Reactive lymphocyte +
TPP refractometer 5.8-7.8 g/dL 9.4 7 6.1 6.9
Notes: ND- not determined
Table 3. Serum biochemical profile monitoring of Alba
Analyte Reference ranges Units T0 T24 T42 T85 T148 T265
Total calcium 8.7-11.8 mg/dL 10.5 10.7 10.2 9.6 9.8 10.6
Phosphates 2.5-5.0 mg/dL 4.6 2.6 4.7 4 3.5 3.5
Iron 80-190 µg/dL 95 321 NT NT 116 200
Total proteins 5.8-7.8 g/dL 11.5 12.3 9.4 7.4 6 6
Albumin 2.6-4.1 g/dL 1.9 2.5 2.6 2.9 3.2 3.1
Globulins 2.5-4.5 g/dL 9.7 9.8 6.8 4.5 2.8 2.9
A/G ratio 0.5-1.5 0,20 0.25 0.38 0.64 1.14 1.06
Fructosamine 170-430 µmol/L 198 252 NT NT 325 329
C-reactive protein 0.0-0.30 mg/dL 2.3 0.2 0.2 NT 0.3 0.3
Urea 15-55 mg/dL 17 20 33 20 34 14
Creatinine 0.6-1.5 mg/dL 1 1 1 0.9 1.1 0.8
Total bilirubin 0.07-0.30 mg/dL 0.11 0.07 NT 0.2 0.2 0.07
Cholesterol 120-280 mg/dL 206 212 263 280 218 208
Tryglicerides 25-90 mg/dL 75 75 NT NT 52 69
Glucose 80-125 mg/dL 104 101 117 114 105 120
Alkaline phosphatase (ALP) 45-250 U/L 180 120 105 104 110 302
Gammaglutamyl transferase (GGT) 2.0-11.0 U/L 4 2 2 1 6 3
Aspartateaminotransferase (AST) 15-40 U/L 75 27 NT NT 35 21
Alanineaminotransferase (ALT) 20-70 U/L 22 22 25 69 174 44
Creatinphosphokinase (CK) 40-185 U/L 177 184 NT NT 69 56
Lactatedehydrogenase (LDH) 20-160 U/L 338 166 NT NT 57 91
Amylase 400-1500 U/L 1228 1362 NT 486 839 563
Sodium 146-156 mEq/L 152 158 157 153 146 156
Potassium 3.9-5.5 mEq/L 4 4 4.5 4 3.6 4.2
Chloride 109-122 mEq/L 115 117 118 117 116 118
Bicarbonate 21-31 mEq/L 24 26 20.5 NT 28 29
Notes: NT- not tested
Table 4. Coagulation profile monitoring of Alba
Analyte Reference Ranges Units T0 T24 T148 T265
Prothrombin time 5.4-8.1 Seconds 9 7.1 7.1 7.3
Partial thromboplastin time 10.7-17.5 Seconds 17.5 15.9 14 11.7
Fibrinogen 125-335 mg/dL 275 241 177 300
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Table 5. Serum protein electrophoresis monitoring of Alba
Analyte Reference ranges Units T0 T24 T85 T148 T265
Albumin 47.5-58.5 % 22.2 20 37.5 52.7 51.7
Alpha-1-globulin 2.6-4.4 % 1.4 1.9 5.7 3.8 3.6
Alpha-2-globulin 10.7-18.0 % 8.7 6.9 15.8 14.3 15.7
Beta-1-globulin 5.9-13.3 % 3.3 6.7 10.9 8.7 11.1
Beta-2-globulin 7.2-14.4 % 9.2 7.3 10.2 8.5 9.5
Gamma globulin 6.6-11.6 % 55.2 57.2 19.9 12 8.4
A/G 0.5-1.5 0.29 0.26 0.6 1.11 1.07
Total protein 5.8-7.8 g/dL 11.5 12.3 8.1 6 6
Table 6. Urinalysis monitoring of Alba
Analyte Reference ranges Units T0 T148
Method of collection Cystocentesis Cystocentesis
Color Yellow NA Yellow-green Yellow
Aspect Clear NA Cloudy ++ Cloudy +
Specific gravity 1018-1045 NA 1035 1030
pH 5-7 NA 8 6
Protein <40 mg/dL 30 Absent
Glucose absent mg/dL Absent Absent
Ketones Absent mg/dL Absent Absent
Urobilinogen Absent mg/dL Absent Absent
Bilirubin Absent mg/dL Absent Absent
Blood Absent RBCs/mcL 50 Absent
Leukocytes Absent WBC/mcL 25 Absent
UP/C ratio 0.1-0.5 NA 0.64 0.15
Cellularity Rare NA Moderate Moderate
RBC 1-5 HPF ++ Absent
WBC 1-5 HPF -/+ -/+
Epitelial cells 1-5 HPF + -/+
Other NA Lipid droplets
Notes: NA – not applicable
Table 7. Lymph node evaluation of Alba
At T0 At T265
Smear quality Good but some hemodilution Very good
General observation Polymorphic cell pattern Polymorphic cell pattern
Lymphoid cells
Small lymphocytes prevalent (ca. 80%),
lymphoblasts or immunoblasts (ca. 10%),
plasmacells (ca. 10%)
Small lymphocytes prevalent,
few immunoblasts and plasmacells
Other cells
A great number of macrophages
some with Leishmania spp Rare mastocytes and macrophages
Mitosis Some occurring but typical Not observed
Conclusion
Lympho-plasmacellular hyperplasia
compatible with Leishmania infection
Normal lymphonode with a
mild increase of plasmacells
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Table 8. Bone marrow monitoring (smear evaluation and PCR) of Alba
Analyte T0 T148
Collection site Iliac crest Sternum
Cellularity Very good Good
Megakariocytes Occurring in all maturation forms Occurring in all maturation forms
Myeloid series
Proliferative, maturative,
and storage cells well represented
Proliferative and maturative cells well




Proliferative and maturative cells
well represented
Other cells
Rare lymphocyte and plasmacells –
macrophages with Leishmania spp. Rare plasmacells
Mitosis Occurring in myeloid and erythroid series
Occurring in myeloid and erythroid series –
some atypical in myeloid
Conclusions
Megakariocyte, myeloid and erythroid series
normal for number and morphology.
Mild hyperplasia of myeloid in comparison to
erythroid series. Macrophages with Leishmania spp.
Megakariocyte series normal for number and
morphology. Myeloid normal for number but
mild sign of dysplasia. Erythroid series normal
for morphology mild prevalence to myeloid.
Anaplasma pahogocytophilum/platys
(PCR+Hybridization Hybprobes) Negative NT
Babesia spp (conventional PCR) Negative NT
Bartonella spp (PCR+SYBR Green R©) Negative NT
Ehrlichia canis
(PCR+Hybridization Hybprobes) Negative NT
Hepatozoon spp (conventional PCR) Negative NT
Leishmania infantum
(PCR+Hybridization Hybprobes) Positive (1.212.000.000 copies) Negative (limit 100 copies of kinetoplast)
Rickettsia spp
(PCR+Hybridization Hybprobes) Negative NT
Notes: NT- not tested
Table 9. Treatment monitoring of Alba
T0 (kg. 17.5) T3 (kg. 17.7) T10 (kg. 18.5)
Meglumine antimonate = 85.7 mg/kg SC Meglumine antimonate = 84.7 mg/kg SC Meglumine antimonate = 97.3 mg/kg SC
Allopurinol = 8,6 mg/kg bid OS Allopurinol = 8.5 mg/kg bid OS Allopurinol = 8.1 mg/kg bid OS
Spiramycin = 42,860 UI/kg bid OS Spiramycin = 42,370 UI/kg bid OS Spiramycin = 40,540 UI/kg bid OS
Metronidazole = 7.14 mg/kg bid OS Metronidazole = 7.06 mg/kg bid OS Metronidazole = 6.75 mg/kg bid OS
Glucose 5% = 14.3 ml/kg bid EV Glucose 5% = 14.1 ml/kg bid SC interrupted
Multi-vitamins vials SC Multi-vitamins vials SC Multi-vitamins vials SC
Artificial lacrimal drops TID topical Artificial lacrimal drops TID Artificial lacrimal drops TID
Chloramphenicol/Neomicin eye drops TID topical
Chloramphenicol/
Neomicin eye drops TID
Chloramphenicol/
Neomicin eye drops TID
Topical use on tail
skin of iodopovidone BID
Suspended when the
ulcer was healed
Topical use of combined drug:
Glycol-propilene + malic acid +
benzoic acid + salicylic acid
Topical use of combined drug:
Glycol-propilene + malic acid +
benzoic acid + salicylic acid
Table 9. Treatment monitoring of Alba (Continued)
T24 (kg. 19.1) T42 (kg. 20.3) T85 (kg. 20.8) T148 (kg. 21.3)
Meglumine antimonate = 94.2 mg/kg SC Interrupted at T40
Allopurinol = 7.8 mg/kg bid OS Allopurinol = 7.4 mg/kg bid OS Allopurinol = 4.8 mg/kg bid OS interrupted
interrupted
interrupted
Multi-vitamins vials SC Multi-vitamins tablet OS Multi-vitamins tablet OS interrupted
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Tipicˇna lajsˇmanioza psa redovno vakcinisanog sa Canileish R© vakcinom
Sazˇetak
Uvod
Vakcina protiv lajsˇmanioze pasa (Canileish R©) napravljena
od LiESAp i 54-kDa proteina estrahovanih iz Leishmania
infantum, a uz dodatak muramil-peptida (MDP) kao adju-
vantnog sredstva, koristi se u nekoliko evropskih drzˇava.
Razvijena je da stimulisˇe c´elijski imunitet kod pasa
serolosˇki negativnih na lajsˇmaniozu, kako bi se smanjio
rizik od razvoja infekcije i klinicˇkih manifestacija bolesti.
U ovom cˇlanku je opisan slucˇaj psa sa tesˇkim oblikom
lajsˇmanioze, koji je redovno vakcinisan sa (Canileish R©)
vakcinom i tretiran repelentima i drugim sredstavima protiv
ektoprazita (vektora).
Materijal i metode
“Alba”, engleski seter, intaktna zˇenka stara tri godine dove-
dena je (mart 2015.) sa simptomima dizoreksije, gubitka tje-
lesne mase, sa povisˇenom temperaturom i slabosˇc´u prednjih
nogu. “Alba” je uz prevenciju ekto i endoparazitoza redovno
vakcinisana protiv najcˇesˇc´ih bolesti pasa, te Canileish R© vak-
cinom protiv lajsˇmanioze.
Fizikalnim pregledom (T011) su zabiljezˇeni: indeks tje-
lesne kondicije 2/9, temperatura 39.6 ◦C, umjereno povec´a-
nje perifernih limfnih cˇvorova, seropurulentni iscjedak iz
oka sa fotofobijom i otecˇen i bolan desni karpalni zglob.
Uradena je kompletna krvna slika (CBC), biohemijski
profil, koagulacijski profil, elektroforeza serumskih pro-
teina, serolosˇko testiranje na L. infantum, analiza urina
ukljucˇuju i UP/C omjer, punkcija preskapularnih i popliteal-
nih limfnih cˇvorova, punkcija kosˇtane srzˇi za citologiju i
qPCR na L. infantum.
Rezultati
Razlicˇiti klinicˇki simptomi su se povukli sukcesivno: sla-
bost prednjih ekstremiteta - T3, temperatura i fotofobija -
T10, seropurulentni iscjedak iz oka - T15, blefaritis, lim-
fadenopatija i velike kozˇne promjene repa - T24, tjelesna
tezˇina T42.
Kompletna krvna slika (T0) je pokazala umjerenu mi-
krocitnu neregenerativnu anemiju, blagu neutropeniju i
trombocitopeniju (normalni na T265). Biohemijski profil
(T0) je potvrdio tesˇku hiperproteinemiju (normalne vrijed-
nosti na T85), hipoalbuminemiju (normalno na T42), hiper-
globulinemiju, nizak albuminsko/globulinski omjer (oboje
normalni na T85), i povisˇen C-reaktivni protein (normalan
na T24). Elektroforeza serumskih proteina (T0) je pokazala
hipoalbuminemiju i poliklonalnu hipergamaglobulinemiju
(normalna na T148).
11T: vrijeme u danima od dana prijema (T0) pacijenta
Analizom urina (T0) ustanovljena je hematurija (nor-
malno na T6) i blagi porast omjera proteina i kreatinina u
urinu (normalni na T85). U aspiratima limfnih cˇvorova i
kosˇtane srzˇi (T0) utvrdene su amastigote lajsˇmanije.
Uzorci limfnih cˇvorova i kosˇtane srzˇi bili su negativni
qPCR tehnikom na Babesia spp, Bartonella spp, Ehrlichia
canis, Hepatozoon spp, i Rickettsia spp, ali pozitivni na L.
infantum (negativni na T148 i T265).
IFAT metodom (T0) je ustanovljen izrazito visok titar
antitijela (1:5120), koji se smanjio na 1:320 (T148) i 1:160
(T265). Speed-Leish K R© test je cijelo vrijeme bio pozitivan.
“Alba” je tretirana sa meglumin-antimonatom (SC) i
alopurinolom (PO) u trajanju od 40 dana. Alopurinol je
iskljucˇen na T265. Metronidazol-spiramicin je apliciran
perooralno do T24. Terapija tecˇnostima (fiziolosˇki rastvor
NaCl i 5% glukoze) aplicirana je deset dana, topikalna
terapija repa je prekinuta na T24, a oka na T40.
Interpretacija i zakljucˇak
Ovaj slucˇaj opisuje tipicˇnu klinicˇku i klinicˇko-patolosˇku
sliku lajsˇmanioze nakon neuspjeha vakcine ili neefikasnog/
nedovoljnog imuniteta.
Vlasnik psa je potvrdio korisˇtenje repelenta i drugih
sredstava protiv vektora te redovnu vakcinaciju. Posljednja
doza Canileish R© je aplicirana oko 10 mjeseci prije izbijanja
bolesti.
“Alba” je pokazala brz odgovor na standardnu terapiju.
Svi opisani klinicˇki znaci su se povukli do T27, dok su se
klinicˇko-patolosˇki znaci vrac´ali u normalne granice sukce-
sivno.
Kompletna krvna slika i citolosˇki pregled kosˇtane srzˇi
su se progresivno vratili u normalne granice na T265. S
obzirom na pojavu mikrocitne hipohromne neregenerativne
anemije na T0, moguc´e da je pas zarazˇen u ljeto/jesen 2014.
godine. Biohemijski profil i analiza urina nisu bili sig-
nifikantni od T42, odnosno T85. Elektroforeza serumskih
proteina je znatno odstupala od normalnih vrijednosti na
T0, ali se normalizirala na T148. Neposredna dijagnoza
lajsˇmanioze je postavljena ciljanom punkcijom limfnog
cˇvora i biopsijom kosˇtane srzˇi, za koje je poznato da imaju
visoku specificˇnost i osjetljivost. Senzitivnost oba testa
opada pod djelovanjem terapije tako da qPCR mozˇe pomoc´i
u otkrivanju patogena, i utvrdivanju uspjesˇnosti terapije.
Serolosˇki dokaz antitijela se ne mozˇe koristiti kao potvrda
prisustva parazita u organizmu jer se antitijela jako dugo
zadrzˇavaju.
Opisani slucˇaj potvrduje da i pored vakcinacije postoji
moguc´nost pojave klinicˇkih i drugih znakove lajsˇmanioze,
sˇto treba imati u vidu posebno u podrucˇjima koja su visoko-
rizicˇna za pojavu lajsˇmanioze.
